| Home |
| Program & Agenda • Presentations • Planning Committee |
| Participants |
 |
| Founding Sponsor |
 |
| Sponsors |  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Speakers Jim Alwood
Jim Alwood has been a program manager in the Office of Pollution Prevention and Toxics' Chemical Control Division for 25 years. In addition to extensive experience with new chemical review under TSCA, he works on significant new use rules, TSCA biotechnology issues, and now TSCA nanotechnology issues including directing the stewardship program for nanoscale materials under TSCA. He has a Bachelors of Science degree in Biology from Dickinson College and a Masters Degree in Environmental Science from George Washington University. Walter Andrews
Walter J. Andrews is one of the leaders of Hunton & Williams' insurance coverage group. His practice focuses on contract litigation and insurance coverage litigation and counseling. He litigates coverage and bad faith disputes involving business interruption, construction defects, e-commerce issues, and other emerging claims. These matters involve a variety of insurance contracts, including professional liability, first party property and general liability insurance policies. Mr. Andrews is a member of the FDCC, IADC, DRI, ARIAS and an American Bar Foundation Fellow. Mr. Andrews has testified before Congress and speaks and writes regularly on various litigation topics. His recent articles include Co-author, Rising Contamination, MtBE Lawsuits Help Fuel Demands for 'Stigma Damage', National Underwriter P&C magazine, June 2007; A "Flood of Uncertainty": Contractual Erosion in the Wake of Hurricane Katrina and the Eastern District of Louisiana's Ruling In Re Katrina Canal Breaches Consolidated Litigation, Tulane Law Review, Vol. 81:1277, May 2007; "Welding Fume Exposure Claims and Their Implications Under Contracts for General Liability Insurance," Mealey's Litigation Report, Vol. 2, No. 1, April 2005; "Long-Term Professional Liability Cases: Who Is Responsible For Nursing Home Claims?," Casualty Insurance Committee Newsletter, No. 5, March 2005; "Nanotechnology: Tiny Technology, Big Risk?," Andrews Insurance Coverage Litigation, Vol. 15, December 17, 2004; "Many Faxes: Little Coverage?," Mealey's Emerging Insurance Disputes, Vol. 9, No. 22, November 16, 2004; and "The Vioxx Recall and Its Insurance Implications," Mealey's Emerging Insurance Disputes, Vol. 9, No. 21, Nov. 2, 2004. Dr. John M. Balbus, M.P.H.
Dr. Balbus' background combines training and experience in clinical medicine with expertise in epidemiology, toxicology and risk sciences. He has authored studies and lectures on global climate change and health, transportation-related air pollution, the toxic effects of chemicals, and regulatory approaches to protecting susceptible subpopulations. Dr. Balbus received his A.B. degree in Biochemistry from Harvard University, his M.D. from the University of Pennsylvania, and his M.P.H. from the Johns Hopkins School of Public Health. Prior to joining Environmental Defense, Dr. Balbus spent seven years at The George Washington University, where he was founding Director of the Center for Risk Science and Public Health and served as Acting Chairman of the Department of Environmental and Occupational Health. In addition to the EPA Science Advisory Board, Dr. Balbus is also a member of the National Research Council's Board on Environmental Studies and Toxicology and the EPA Children's Health Protection Advisory Committee. His professional organization memberships include the American College of Physicians, American Public Health Association, Society of Toxicology, and the Society for Risk Analysis. William E. Barr William E. Barr is a Vice President and Senior Technology Risk Specialist of the Chubb Group of Insurance Companies with an emphasis in emerging technologies. Bill is heavily involved in Chubb's Nanotechnology initiative, working with clients in the San Francisco Bay Area, and has spoke frequently on loss control for companies working with nano materials. Of Bill's 39 years with Chubb, twenty-four have been spent dealing directly with High Tech clients and twenty-seven have been in management positions including managing Chubb Western U.S. and Global Technology Loss Control Services. Bill holds a B.S. in Engineering Operations from North Carolina State University, is a Certified Safety Professional (CSP), an Associate in Risk Management (ARM), a member of the American Society of Safety Engineers, and has been a guest lecturer in Industrial Technology courses at California Polytechnic State University. Mark Bunger Mark Bunger leads the Lux Research Biosciences Intelligence practice from the firm's San Francisco office. He has 15 years of business strategy experience, both as a management consultant and a technology analyst. In this time, he has advised more than 40 Fortune 500 corporations, led hundreds of engagements, and authored over 60 reports and other publications. Before joining Lux Research, Mark was a Principal Analyst at Forrester Research, where he studied and advised clients in manufacturing industries including automotive and aerospace. Prior to that, Mark was a Managing Director at European technology consultancy Icon Medialab (now LB International). He also co-founded the leading online promotional currency company, SoftCoin, which manages multimillion-dollar campaigns for clients such as Kodak, Proctor & Gamble, Frito-Lay, and Nokia. The first six years of Mark’s career were spent at Accenture in the U.S. and Europe, where he was a consultant in a variety of industries and technologies. Mark and his work have appeared in leading business journals, including CNN, CNBC, The Wall Street Journal, and the Financial Times. Mark's education includes International Marketing at Malardalen Polytechnic in Sweden, and Market Research at the University of Texas in the U.S. In addition, Mark studied biochemistry through the University of California at Berkeley's extension program, and currently assists part-time in a lab at the UCSF Department of Neurology. He speaks English, Swedish, and German, and is conversant in French, Spanish, and four other languages. He has served as Chairman and Vice-Chair of the Swedish-American Chamber of Commerce on the regional and national level, respectively. Mark and his family split the year living in California and Sweden. Dr. Richard Canady, DABT Rick Canady is an Senior Advisor in the firm's Washington, DC office. He specializes in nanotechnology and risk assessment. Prior to joining the firm, Dr. Canady was a Senior Science Policy Analyst for the FDA Office of the Commissioner where he represented the FDA on risk assessment and toxicology policy and research issues of particularly sensitive and multi-centered nature. Dr. Canady has led multidisciplinary teams of policy and technical experts in the resolution of a wide range of health risk management issues over a career that spans emerging technology uses, emerging food and environmental contaminants, and medical product development. He has experience in government regulatory policy at the executive level integrating across product review centers for the FDA Office of the Commissioner and Federal Agencies for the Executive Office of the President. His experience includes substantial international work, leading policy and technical analysis teams within the Organization for Economic Cooperation and Development, the World Health Organization, and the Food and Agriculture Organization as well as in direct bilateral interactions with the European Commission, EU member countries, Canada, Japan, and Australia. Dr. Canady received his Ph.D. from Rockefeller University in Neurophysiology, Physiology, Behavior. He earned his B.S. in Psychology, Biology from the University of Michigan.
Dr. Kenneth Dawson Kenneth Dawson, Ph.D., is Director of the Centre for BioNano Interactions (CBNI), which is the Irish national platform for excellence in the interaction of nanoparticles with living systems (www.cbni.eu). Prof Dawson is currently steering the development of this as a national core excellence facility in bionanosciences, and is the lead investigator of the Bionanoscience Activities in University College Dublin. He is Chair of Physical Chemistry, and a Director of the Complexity Centre in Rome. Prof. Dawson’s professional roles include representing Ireland on the OECD and ISO working groups on standards for Nanotechnology, as well as acting as a European representative in ICON (International Council on Nanotechnology). He is currently Editor of Current Opinion in Colloid Science, Senior Editor of Physica, and a former President of the European Colloid and Interface Society. Professor Dawson is Chairing the launch of the International Alliance on NanoEHS Harmonisation (http://nanoehsalliance.org/), a new global partnership of scientists from EU, US, and Japan to drive efforts to build consensus and standardized protocols for nanotoxicity testing. This has attracted support from governments, agencies, institutions, industry, and NGO’s as a vehicle to help ensure safe implementation of nanotechnology. Dr. Hilary Godwin Dr. Hilary Godwin joined the UCLA faculty in 2006 and is currently a Professor in the Environmental Health Sciences Department and Associate Dean for Academic Programs in the School of Public Health. She received a B.S. in Chemistry from the University of Chicago in 1989 and a Ph.D. Physical Chemistry from Stanford University in 1994. She conducted postdoctoral research from 1994-1996 at the Johns Hopkins University School of Medicine in the Department of Biophysics and Biophysical Chemistry, where she was a National Institutes of Health postdoctoral fellow. Prior to joining the faculty at UCLA, Dr. Godwin was on the faculty of the Department of Chemistry at Northwestern University where she was an Assistant Professor (1996-2000), Associate Professor (2000-2006), Associate Chair (2003-2004), and Chair (2004-2006) of Chemistry. Dr. Godwin has received several awards, including a Camille Dreyfus Teacher-Scholar Award, an Alfred P. Sloan Research Fellowship, a National Science Foundation CAREER Award, a Burroughs Wellcome Fund Toxicology New Investigator Award, and a Camille and Henry Dreyfus New Faculty Award. She is a Howard Hughes Medical Institute Professor. Dr. Godwin's research focuses on elucidating the molecular toxicology of lead and the mechanisms by which nanoparticles enter cells and elicit biological responses. She also works actively with community groups to prepare for and diminish the impact of climate change on public health. Dr. Leroy Hood Dr. Hood's research has focused on the study of molecular immunology, biotechnology, and genomics. His professional career began at Caltech where he and his colleagues pioneered four instruments - the DNA gene sequencer and synthesizer, and the protein synthesizer and sequencer - which comprise the technological foundation for contemporary molecular biology. Dr. Hood moved to the University of Washington as founder and Chairman of the cross-disciplinary Department of Molecular Biotechnology. In 2000, he co-founded the Institute for Systems Biology in Seattle, Washington to pioneer systems approaches to biology and medicine. In addition to his groundbreaking scientific contributions, Dr. Hood has also played a role in founding more than 14 biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta. He is currently pioneering systems medicine and the systems approach to disease. He is a 2005 recipient of the Heinz Award for Technology, the Economy and Employment for his development and commercialization of high throughput biology (automated protein and DNA sequencing). Dr. Saber M. Hussain Saber Hussain is a leading scientist at the Applied Biotechnology, Human Effectiveness Directorate, Air Force Research Laboratory, WPAFB, AFB, OH. He is full affiliated faculty at the Wright State University, and adjunct faculty at the University of Dayton. Before joining the Air Force Research Laboratory Dr. Hussain was research assistant professor at the Veterinary School of Medicine, Tuskegee University (1997-1999). He is the author of more than 60 scholarly publications. He is author or co-author of 60 peer-reviewed articles, 4 book chapters, several technical reports, and 150 technical abstracts. He has obtained several awards based on his outstanding contribution in research related nanoparticles and their biological effects. He serves as editorial member of Toxicological Sciences and International Journal of Toxicology. Dr. Hussain serve in several committees and organized international symposia and scientific meetings related to toxicology. His current research focuses on biological interaction and toxicity evaluation of engineered nanoparticles of interest to the US Air Force. Besides toxicology, he has a deep commitment to developing biological interaction of nanomaterials a multidisciplinary approach to develop biofunctionalized nanomaterials and exploit their properties for biological application Dr. James Hutchison Dr. James Hutchison joined the faculty at the University of Oregon (UO) in the fall of 1994. He is currently the Lokey-Harrington Professor of Chemistry and Associate Vice President for Research and Strategic Initiatives. His research interests are in green chemistry, materials chemistry and nanoscience. He led the development of the UO's nation-leading program in "green" (environmentally-benign) organic chemistry and launched the university's pioneering Center in Green Nanoscience. He is a member of the leadership team for the Oregon Nanoscience and Microtechnologies Institute (ONAMI) and founded, and now directs, the ONAMI’s Safer Nanomaterials and Nanomanufacturing Initiative. He is a member of the Governing Board of the ACS Green Chemistry Institute. He has won a number of awards, including an NSF-CAREER award and the 2003 Oregon Academy of Science Outstanding Teacher of Science and Math in Higher Education. Hutchison is an Alfred P. Sloan research fellow and a Camille Dreyfus teacher-scholar. He is the author of 90 refereed publications, three book chapters and a text book ("Green Organic Chemistry: Strategies, Tools and Laboratory Experiments"). Steve Knutson Steve Knutson directs North America's Emerging Issues Management team consisting of Zurich's most talented claims, legal, underwriting and risk engineering executives. He also serves on Zurich's Global Emerging Risk Group that focuses on the impact of emerging issues from the perspective of Zurich's international businesses. Both organizations develop and execute strategies to maximize upon the opportunities and minimize the threats presented by emerging issues. Steve manages Zurich's multifaceted global strategy to address the challenges of nanotechnology. Over the course of his 39 years in the commercial insurance industry, Steve has held various underwriting management and executive positions of which the last 20 years have been with Zurich. Education and affiliations include B.S, Business Administration, Drake University; Executive Programs, Kellogg School of Northwestern University. John C. Monica, Jr.
John Monica is a partner in the Washington, D.C. office of Porter Wright Morris & Arthur LLP where he chairs the firm's multi-disciplinary Nanotechnology Practice Group. Mr. Monica is a leading author on nano-related environmental, health, and safety legal issues and is an editor of the Nanotechnology Law & Business peer-reviewed journal. He is also releasing in 2009 the full-length reference text Nanotechnology Law & Policy through West/Thomson-Reuters and regularly contributes to Nanotechnology Law Report, a nano-related blog at www.nanolawreport.com. Mr. Monica received his B.A. from Northwestern University and his J.D. from George Washington University. Of particular interest to NHSF participants may be two of Mr. Monica's 2008 articles -- FDA Labeling of Cosmetics Containing Nanoscale Materials and A Nano-Mesothelioma False Alarm. Dr. Vladimir Murashov
Dr. Vladimir Murashov is a Special Assistant on Nanotechnology to the Director of the National Institute for Occupational Safety and Health in the U.S. Department of Health and Human Services in Washington, D.C. Prior to his appointment as Special Assistant on Nanotechnology, Dr. Murashov served as a Senior Scientist in the Office of the Director, NIOSH from 2003-2005. Dr. Murashov received his Ph.D. in Chemistry from Dalhousie University in Halifax, Canada in 1998. He completed his postdoctoral studies in University of British Columbia in Vancouver, Canada in 2001, when he joined NIOSH as a Senior Service Fellow to conduct computational chemistry studies. Dr. Murashov is a globally recognized expert in nanotechnology safety and health. He serves as a subject matter expert on various panels and advisory boards and is frequently invited to make presentations at major international conferences on nanotechnology. Dr. Murashov has been a member of the Nanoscale Science, Engineering and Technology Subcommittee of the National Science and Technology Council’s Committee on Technology and its working groups representing NIOSH since 2004. He leads projects under the International Organization for Standardization Technical Committee on Nanotechnology and Organization for Economic Cooperation and Development Working Party on Manufactured Nanomaterials. He has written numerous articles in the area of computational and experimental materials chemistry. George R. Nethercutt, Jr.
George R. Nethercutt, Jr. is a former US Congressman who represented the 5th District of Washington from 1995-2005 in the US House of Representatives. He served as a member of the House Appropriations Committee (Defense, Interior and Agriculture Subcommittees) and the House Science Committee (Energy and Space & Aeronautics Subcommittees). He currently serves as United States Chairman, Permanent Joint Board on Defense-US/Canada, and serves on the boards of Hecla Mining Company, an international gold and silver mining company; ARCADIS NV, an international company that provides consultancy, design, engineering and management services in the fields of infrastructure, environment and buildings; the Washington Policy Center and the Juvenile Diabetes Research Foundation International. He is Chairman of Nethercutt Consulting LLC, a Washington, DC based consulting firm, and the George Nethercutt Foundation, a non-profit organization dedicated to improving civics and leadership education for college students. Mr. Nethercutt lectures regularly on the state of policy matters in Congress.
William S. Rogers, Jr.
William S. Rogers, Jr. is a partner and concentrates his practice in the Commercial Litigation Department at Day Pitney, LLP's Boston Office. Day Pitney, LLP is a 400-attorney law firm with nine offices across the Northeastern and Mid-Atlantic Regions of the U.S., from Boston to Washington, D.C. Mr. Rogers represents a broad array of technology companies and their representatives, product manufacturers, product vendors, and product purchasers in commercial disputes. Mr. Rogers has tried over 35 major cases to conclusion in Courts and Commercial Arbitrations in a 22 year career. He has tried and managed complex commercial litigations, which often involve proprietary, trade secret and technology driven issues involving both closely held private businesses and publicly traded companies. These include complex product warranty and liability cases including a wide variety of products, from hand-held power tools, electrical and power sub-components, software products, microprocessors and integrated circuits, silicon wafers, and heavy industrial machinery. Mr. Rogers advises clients concerning their duties and obligations under the Consumer Product Safety Improvement Act of 2008. Mr. Rogers has been working in the emerging field of nanotechnology compliance and risk management, including presenting a panel discussion on nanotechnology regulation, policy, and product safety and liability risk at Nanotech 2009 in Houston, Texas in May 2009. Mr. Rogers is admitted to practice in all state and federal courts in the Commonwealth of Massachusetts and the United States Supreme Court. He has also been admitted specially as lead trial counsel for cases in the State Courts of Connecticut, Rhode Island, Maine, and California. Prior to joining Day Pitney, LLP, Mr. Rogers was a Shareholder in Greenberg Traurig., LLP's multi-disciplinary Nanotechnology practice, and has joined a similar group at Day Pitney, LLP. He has a B.S. in Management from the Whitman School of Management at Syracuse University, and a J.D. from Boston University School of Law.
Dr. Charanjeet Singh
Dr. Charanjeet Singh is currently the programme manager for a three year international, interdisciplinary project entitled PROSPEcT: Ecotoxicology Test Protocols for Representative Nanomaterials in Support of the OECD Sponsorship Programme. The project is funded by the United Kingdom government and industry, and will develop essential and seminal test methods and data on two agreed nanomaterials (nano-scale cerium oxide and zinc oxide) that are of particular commercial relevance to the UK. Prior to joining the NIA, Dr. Singh worked for Thomas Swan & Co., Ltd. as a Nanotechnologist where he helped established a successful carbon nanotube manufacturing facility and product. The technology was a commercialisation of the research initially developed from the University of Cambridge where I received my doctorate degree in nanotube synthesis. Dr. Singh also represents the UK as an expert on the International Standards Organisation Technical Committees on Nanotechnology (ISO/TC 229). Dr. Robert Tanguay Dr. Robert Tanguay is an Associate Professor in the Department of Environmental and Molecular Toxicology, the Director of the Sinnhuber Aquatic Research Laboratory, and the Director of the NIEHS Toxicology Training Grant. He received his PhD in Biochemistry from the University of California-Riverside (1995) and postdoctoral training in developmental toxicology from the University of Wisconsin-Madison (1996-1999). Over the past 11 years he has exploited the molecular and genetic advantages of zebrafish to define the molecular mechanism by which chemicals and drugs adversely affect vertebrate development and function. His group has demonstrated that embryonic zebrafish are well-suited to rapidly evaluate in vivo nanomaterial/biological interactions. Dr. Justin Teeguarden Justin G. Teeguarden is a senior research scientist with the Pacific Northwest National Laboratory where he conducts research within a multidisciplinary team studying the relationship between the physicochemical properties of nanomaterials and their biocompatibility. His major research focus is in the areas of nanomaterial pharmacokinetics and dosimetry, both in vivo and in vitro, and the development of integrated computational models of cellular/tissue dosimetry and biological response. He is the principal investigator on studies of the pharmacokinetics of organic chemicals and metals and develops physiologically based pharmacokinetic models of chemical kinetics for application in study design and risk assessment for both private companies and the United States Environmental Protection agency. Through Society of Toxicology symposia, specialty sections and continuing education courses, Justin has promoted the application of the fundamental sciences in nanomaterial risk assessment. He serves on the National Toxicology Program Board of Scientific Councilors, and has served on a variety of U.S. EPA and NIH review panels. Justin received his PhD in toxicology from the University of Wisconsin, Madison, and is board certified in toxicology.
Dr. Michael Yost Dr. Michael Yost is a Professor and the director of the Exposure Sciences program in the Department of Environmental and Occupational Health Sciences at University of Washington. He received his Ph.D. from the University of California at Berkeley in Environmental Health Sciences with minors in Electrical Engineering and Biostatistics. Dr. Yost's research focuses on exposure assessment methods, modeling, and novel instrumentation for chemical and aerosol sampling. Professor Yost has developed optical sampling methods for air pollutants based on Open Path Fourier Transform Infrared (OP-FTIR) spectroscopy, and established the Optical Remote Sensing (ORS) lab at the University of Washington. The ORS lab has deployed a variety of spectroscopic and laser instruments for rapidly detecting gases and aerosols in the environment. Dr. Yost has published more than 80 refereed articles, holds 7 US patents, and has had major research supported by grants from NIOSH, NIEHS, USDOE, USDOD and USEPA. |
|
| Website will be updated with additional
details as available. Home | Program & Agenda | Invited Participants | Schedule |
|